Expanded Access Cost Distribution: FDA Clarifies New Rules For Charging Patients
Executive Summary
Revised draft guidance makes clear that sponsors may charge all patients a flat administrative fee to cover ‘startup’ costs, regardless of when they join.
You may also be interested in...
US FDA clarifies rules on expanded access to investigational drugs
All applications for patients to receive an investigational drug under the US Food and Drug Administration's expanded access regulation must undergo a full review by an institutional review board, the agency has clarified in a draft guideline1,2. In a separate document, the FDA also explains the circumstances in which it may be appropriate for sponsors to charge patients for being allowed access to investigational drugs3,4.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?